Silencing collapsin response mediator protein-2 reprograms macrophage phenotype and improves infarct healing in experimental myocardial infarction model

Journal of Inflammation

Dong-Mei Zhang²  Yun Wang³  Shu-Cai Jiang¹  Qiang Liu¹  Guo-Long Zhao³  Long-Shu Zhou³ 

[1] Department of Neurosurgery, General Hospital of Ningxia Medical University, Ningxia Medical University, Yinchuan 750004, People’s Republic of China;Department of Anesthesiology, General Hospital of Ningxia Medical University, Ningxia Medical University, Yinchuan 750004, People’s Republic of China;Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, Ningxia Medical University, Yinchuan 750004, People’s Republic of China

关键词: Fibrosis;    Myocardial infarction;    ApoE−/−;    Inflammation;    Phenotypes;    Macrophages;    Collapsin response mediator protein-2;   

Others  :  1134150
DOI  :  10.1186/s12950-015-0053-8

 received in 2014-10-21, accepted in 2015-01-19,  发布年份 2015

【 摘 要 】

Background

Delayed M1 toward M2 macrophage phenotype transition is considered one of the major causes for the impaired healing after myocardial infarction (MI). While searching for molecules that modulate M1 and M2 macrophage polarization, we identified collapsin response mediator protein-2 (CRMP2) as a novel molecule involved in macrophage polarization to M1. In this study, we evaluated the effect of silencing CRMP2 on macrophage polarization, inflammation and fibrosis post myocardial infarction.

Methods

CRMP2 expression was assessed with Western blotting or immunohistochemistry. Macrophage phenotypes were measured with flow cytometry, quantitative real-time PCR (qPCR), Western blotting or immunohistochemistry. CRMP2 siRNA was delivered into the macrophages infiltrated in the wound of ApoE^−/− mice through lipidoid nanoparticle, and fibrosis, leukocyte infiltration and inflammation parameters were measured with qPCR. Infarct size was measured with Masson’s trichrome staining. Echocardiography was performed to assess ventricular systolic dimension, left ventricular diastolic dimension, anterior wall thickness and posterior wall thickness. Student’s t-test (for 2 groups) and ANOVA (for > 2 groups) were used for statistical analyses.

Results

CRMP2 was expressed in a higher level in M1 macrophages than M2 subsets, and CRMP2 RNA interference (RNAi) resulted in a switch of bone marrow-derived macrophages from M1 to M2 phenotype. High level of CRMP2 was also observed in the macrophages infiltrated in the infarct area 3 days post MI in both wildtype (WT) and ApoE^−/− mice, and the expression of CRMP2 retained in the infiltrated macrophages of ApoE^−/− mice but not in that of WT mice 10 days after MI. Nanoparticle-mediated delivery of CRMP2 siRNA to ApoE^−/− mice with MI resulted in dramatic switch of wound macrophages from M1 to M2 phenotype, marked decrease in inflammation and fibrosis, and significant attenuation of post-MI heart failure and mortality.

Conclusion

CRMP2 is highly expressed in M1 macrophages and silencing CRMP2 reprograms macrophage phenotype and improves infarct healing in atherosclerotic mice.

【 授权许可】

   
2015 Zhou et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Fig.3.

【 参考文献 】

• [1]Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, et al.: CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005, 96:881-9.
• [2]Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M: Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013, 229:176-85.
• [3]Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al.: The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007, 204:3037-47.
• [4]Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, et al.: Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009, 54:130-8.
• [5]Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al.: Myocardial infarction accelerates atherosclerosis. Nature 2012, 487:325-9.
• [6]Gordon S: Targeting a monocyte subset to reduce inflammation. Circ Res 2012, 110:1546-8.
• [7]Harel-Adar T, Ben Mordechai T, Amsalem Y, Feinberg MS, Leor J, Cohen S: Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci U S A 2011, 108:1827-32.
• [8]Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al.: Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011, 29:1005-10.
• [9]Arimura N, Menager C, Kawano Y, Yoshimura T, Kawabata S, Hattori A, et al.: Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol Cell Biol 2005, 25:9973-84.
• [10]Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM: Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 1995, 376:509-14.
• [11]Hensley K, Venkova K, Christov A, Gunning W, Park J: Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 2011, 43:180-91.
• [12]Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimura T, Shiromizu T, et al.: CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol 2002, 4:583-91.
• [13]Gu Y, Ihara Y: Evidence that collapsin response mediator protein-2 is involved in the dynamics of microtubules. J Biol Chem 2000, 275:17917-20.
• [14]Yuasa-Kawada J, Suzuki R, Kano F, Ohkawara T, Murata M, Noda M: Axonal morphogenesis controlled by antagonistic roles of two CRMP subtypes in microtubule organization. Eur J Neurosci 2003, 17:2329-43.
• [15]Varrin-Doyer M, Vincent P, Cavagna S, Auvergnon N, Noraz N, Rogemond V, et al.: Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12-induced T lymphocyte migration. J Biol Chem 2009, 284:13265-76.
• [16]Vincent P, Collette Y, Marignier R, Vuaillat C, Rogemond V, Davoust N, et al.: A role for the neuronal protein collapsin response mediator protein 2 in T lymphocyte polarization and migration. J Immunol 2005, 175:7650-60.
• [17]Vuaillat C, Varrin-Doyer M, Bernard A, Sagardoy I, Cavagna S, Chounlamountri I, et al.: High CRMP2 expression in peripheral T lymphocytes is associated with recruitment to the brain during virus-induced neuroinflammation. J Neuroimmunol 2008, 193:38-51.
• [18]Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, et al.: In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J Am Coll Cardiol 2014, 63:1556-66.
• [19]Luo C, Chen M, Madden A, Xu H: Expression of complement components and regulators by different subtypes of bone marrow-derived macrophages. Inflammation 2012, 35:1448-61.
• [20]Gersuk GM, Razai LW, Marr KA: Methods of in vitro macrophage maturation confer variable inflammatory responses in association with altered expression of cell surface dectin-1. J Immunol Methods 2008, 329:157-66.
• [21]Song WJ, Du JZ, Sun TM, Zhang PZ, Wang J: Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small 2010, 6:239-46.
• [22]Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al.: A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-9.
• [23]Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al.: IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011, 12:231-8.
• [24]Zhang Z, Li S, Cui M, Gao X, Sun D, Qin X, et al.: Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Res Cardiol 2013, 108:333.
• [25]Sun G, Li M, Jiang XS, Li L, Peng ZH, Mu NN: Transthoracic Doppler echocardiography to predict optimal tube pulsing window for coronary artery CT angiography. Eur J Radiol 2012, 81:2215-20.
• [26]Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM: Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012, 2012:948098.
• [27]Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG: Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009, 18:482-96.
• [28]Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al.: The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010, 11:936-44.
• [29]Panizzi P, Swirski FK, Figueiredo JL, Waterman P, Sosnovik DE, Aikawa E, et al.: Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol 2010, 55:1629-38.
• [30]Nahrendorf M, Pittet MJ, Swirski FK: Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010, 121:2437-45.
• [31]Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K: Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-61.
• [32]Hamilton JA: Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008, 8:533-44.
• [33]Medzhitov R, Horng T: Transcriptional control of the inflammatory response. Nat Rev Immunol 2009, 9:692-703.
• [34]Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-11.
• [35]Swirski FK, Nahrendorf M: Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013, 339:161-6.
• [36]Katsuki S, Matoba T, Nakashiro S, Sato K, Koga J, Nakano K, et al.: Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 2014, 129:896-906.
• [37]Sigovan M, Boussel L, Sulaiman A, Sappey-Marinier D, Alsaid H, Desbleds-Mansard C, et al.: Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model. Radiology 2009, 252:401-9.
• [38]Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al.: Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009, 458:1180-4.
• [39]Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, et al.: Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Molecular therapy. Nucleic acids 2012, 1:e4.
• [40]Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-30.